Bravo Shareholders: Thoma Bravo Acquires NextGen Healthcare for $1.6 Billion

In a significant move within the healthcare data sector, Thoma Bravo, a leading private equity firm, has announced its acquisition of NextGen Healthcare Inc. for a substantial $1.6 billion.

Under the terms of the acquisition, NextGen shareholders will receive an impressive $23.95 per share in cash, representing a remarkable 46.4% premium over the stock's closing price on August 22. This generous offer reflects Thoma Bravo's confidence in the potential of NextGen and its commitment to maximizing shareholder value.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Since the rumors of a potential sale emerged on August 22, NextGen's shares have experienced a remarkable surge, rising by over 40%. This surge continued even after the announcement, with shares rising by an additional 14% on the day of the acquisition. This Heated market activity underscores the positive sentiment surrounding the deal and showcases the confidence investors have in the future prospects of the combined entity.

NextGen Healthcare, a well-established player in the healthcare data industry and a Nasdaq-listed corporation since 1982, will transition to private ownership as a result of this acquisition. This shift is expected to provide the company with increased operational flexibility and strategic freedom, which will be crucial in navigating the rapidly evolving healthcare landscape.

David Sides, President and CEO of NextGen Healthcare, expressed his optimism about the deal, emphasizing that the partnership with Thoma Bravo will not only enhance shareholder value but also provide the company with vital resources, including capital and expertise. This infusion of resources is poised to catalyze the company's growth and innovation efforts, ultimately benefiting both shareholders and clients.

Thoma Bravo's Vice President, Peter Hernandez, echoed this sentiment, highlighting the potential for accelerated product investments aimed at improving patient outcomes. Thoma Bravo's longstanding interest in NextGen's business trajectory suggests that the private equity firm has a clear vision for how the combined entity can drive positive change in the healthcare data sector.

With a two-week surge of over 40% and a remarkable 30% rise in September alone, NextGen Healthcare's stock performance further underscores the market's approval of this acquisition and its positive impact on the company's valuation.

With the infusion of resources and expertise, the combined entity is poised for a dynamic future, focused on advancing patient outcomes and delivering value to stakeholders across the healthcare ecosystem.